What National HealthCare Shares' Earnings Drop Means For Shareholders
- National HealthCare Corporation reported third quarter 2026 revenue of US$407.97 million compared with US$382.66 million a year earlier, while net income declined to US$13.64 million and diluted earnings per share from continuing operations moved to US$0.85 from US$2.50.
- For the first nine months of 2026, National HealthCare recorded higher revenue of US$1.20 billion versus US$1.13 billion and lower net income of US$89.81 million compared with US$95.17 million, and the board affirmed a regular quarterly dividend of US$0.67 per share payable in January 2027.
- Attention now turns to how National HealthCare's weaker earnings, alongside a maintained dividend, shape the broader investment narrative for investors.
What Is National HealthCare's Investment Narrative?
To own National HealthCare, you need to be comfortable with a fairly capital intensive care model that leans on skilled nursing, inpatient facilities, and homecare rather than asset light software style economics. The draw is a diversified mix of inpatient services, homecare and hospice, and ancillary operations that together produced US$1.20b in revenue for the first nine months of 2026. Recent quarterly earnings softness, with net income of US$13.64 million, highlights execution pressure on costs and mix rather than a collapse in demand.
The board keeping the US$0.67 quarterly dividend in place signals confidence in cash generation. In the shorter term, that choice tightens the margin for error if profitability remains under strain. Investors are weighing that against a P/E of 28.8x that already prices in solid execution, plus high quality earnings and a track record of 10.4% annual profit growth over five years. The stock has risen strongly over one year, even with a roughly 9% retreat over the last month, which suggests expectations are anything but low.
That said, there is a quieter issue around National HealthCare that only becomes obvious once you look closely at ...
There's only one way to know the right time to buy, sell or hold National HealthCare. Head to Simply Wall St's company report for the latest analysis of National HealthCare's Fair Value.
Exploring Other Perspectives
Two members of the Simply Wall St Community have published fair value views on National HealthCare that span from US$0.22 to US$488.12, a very wide bracket for one stock. That spread sits against fresh earnings pressure and an affirmed dividend. This gives you strong reasons to compare multiple viewpoints before forming your own stance.
Explore another National HealthCare fair value estimate, including one that suggests as much as 132% upside from the current price!
Form Your Own Verdict
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.
- A great starting point for your National HealthCare research is our analysis highlighting 2 key rewards and 1 important warning sign that could inform your investment decision.
- See our latest analysis for National HealthCare. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate National HealthCare's overall financial health at a glance.
Looking For More Investment Ideas Beyond National HealthCare?
Once you have a view on National HealthCare, it can help to compare similar opportunities and very different ones side by side. The Simply Wall St Screener lets you filter for the mix of income, quality and risk that actually fits your own playbook rather than relying on a single stock.
- For investors who want income without stretching too far on risk, you can review a curated set of 29 resilient stocks with low risk scores that may suit a more conservative portfolio.
- If you prefer to focus on balance sheet strength and underlying fundamentals, use the list of solid balance sheet and fundamentals (23 results) to find businesses that might better match your criteria.
- Those hunting for underfollowed ideas can scan a 20 high quality undiscovered gems and see which lesser known stocks line up with your return and risk preferences.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com